Joseph Ballard Bogardus
Bristol-Myers Squibb
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joseph Ballard Bogardus.
Pharmaceutical Research | 1994
Mehdi Paborji; Nancy L. Pochopin; William P. Coppola; Joseph Ballard Bogardus
Chimeric L6 is a mouse–human monoclonal antibody specific for tumor cell-associated antigens. The factors affecting the physical and chemical stability of chimeric L6 were assessed at elevated temperatures (30–60°C) and by multiple freezing and thawing. Three routes of degradation were observed: chemical degradation to smaller molecular weight species, irreversible aggregation, and formation of a reversible dimer. The specific pathway depended on the stress condition applied and the pH, with maximal overall stability to both thermal stress and multiple freezing/thawing observed at about pH 5.5. Other factors including antibody concentration, buffer concentration, NaCl concentration, and agitation had minimal influence on the stability. Commonly used sugars, polyhydric alcohols, and amino acids effectively prevented freeze/thaw-induced aggregation.
International Journal of Pharmaceutics | 2000
Rajesh B. Gandhi; Joseph Ballard Bogardus; David E. Bugay; Robert Kevin Perrone; Murray Arthur Kaplan
Three solid state forms of stavudine designated forms I, II and III have been identified and characterized. Forms I and II are anhydrous polymorphs whereas form III is hydrated and is pseudopolymorphic with forms I and II. Physico-chemical and thermodynamic properties of the three solid state forms have been characterized. Solid-state stability and potential for interconversion of the forms to aid in the selection of preferred form for development and commercialization has been studied. Conditions of recrystallization governing the formation of thermodynamically most stable polymorphic form I devoid of other forms was identified.
Pharmaceutical Research | 1995
Nancy P. Barbour; Mehdi Paborji; Thomas C. Alexander; William P. Coppola; Joseph Ballard Bogardus
Chimeric BR96-doxorubicin conjugate (BR96-DOX) is an immunoconjugate designed to specifically target and kill certain tumor cells. The linker between the chimeric BR96 antibody and DOX is an acid-labile hydrazone group which was designed to undergo lysosomal hydrolysis to release DOX in vivo. Stability studies indicated that acid-catalyzed hydrazone hydrolysis was the major degradation route in vitro. Even under optimal conditions of pH and temperature, the stability of BR96-DOX in solution was not acceptable for long-term storage. Lyophilization of BR96-DOX in the presence of added sugars, such as lactose or sucrose, and subsequent storage of the lyophile under refrigeration significantly improved the stability. Therefore lyophilization appears to be a viable approach for achieving long-term stabilization of BR96-DOX.
Archive | 2002
Joseph Ballard Bogardus; Robert Kevin Perrone; Krishnaswamy Srinivas Raghavan; Sailesh A. Varia
Archive | 1994
Murray Arthur Kaplan; Lawan Phusanti; Robert Kevin Perrone; Scott R. Stenberg; Shreeram Agharkar; Joseph Ballard Bogardus
Archive | 1989
Mehdi Paborji; Joseph Ballard Bogardus; Shreerham Narahari Agharkar; William P. Coppola
Archive | 1985
Murray Arthur Kaplan; Michael Winston Lovell; Joseph Ballard Bogardus
Archive | 1996
Rajesh B. Gandhi; Joseph Ballard Bogardus; Peter Michael Garofalo; Timothy Richard Marr; Robert Kevin Perrone; Murray Arthur Kaplan
Archive | 1988
Murray Arthur Kaplan; Robert Kevin Perrone; Joseph Ballard Bogardus
Archive | 1986
Murray Arthur Kaplan; Robert Kevin Perrone; Joseph Ballard Bogardus